Resection and survival data from a clinical trial of glioblastoma multiforme-specificIRDye800-BBNfluorescence-guided surgery

doi:10.1002/btm2.10182

	Resection and survival data from a clinical trial of glioblastoma multiforme-specificIRDye800-BBNfluorescence-guided surgery
	He, Kunshan1,2 ; Chi, Chongwei2 ; Li, Deling 3,4; Zhang, Jingjing 5; Niu, Gang 6; Lv, Fangqiao 7; Wang, Junmei 8; Che, Wenqiang 3,4; Zhang, Liwei 3,4; Ji, Nan 3,4; Zhu, Zhaohui 5; Tian, Jie 1,2; Chen, Xiaoyuan 6
发表期刊	BIOENGINEERING & TRANSLATIONAL MEDICINE
	2020-08-31
页码	9
通讯作者	Ji, Nan(cnpsycho@163.com) ; Zhu, Zhaohui(zhuzhh@pumch.cn) ; Tian, Jie(jie.tian@ia.ac.cn) ; Chen, Xiaoyuan(chen9647@gmail.com)
摘要	Supra-maximum surgical tumor resection without neurological damage is highly valuable for treatment and prognosis of patients with glioblastoma multiforme (GBM). We developed a GBM-specific fluorescence probe using IRDye800CW (peak absorption/emission, 778/795 nm) and bombesin (BBN), which (IRDye800-BBN) targets the gastrin-releasing peptide receptor, and evaluated the image-guided resection efficiency, sensitivity, specificity, and survivability. Twenty-nine patients with newly diagnosed GBM were enrolled. Sixteen hours preoperatively, IRDye800-BBN (1 mg in 20 ml sterile water) was intravenously administered. A customized fluorescence surgical navigation system was used intraoperatively. Postoperatively, enhanced magnetic resonance images were used to assess the residual tumor volume, calculate the resection extent, and confirm whether complete resection was achieved. Tumor tissues and nonfluorescent brain tissue in adjacent noneloquent boundary areas were harvested and assessed for diagnostic accuracy. Complete resection was achieved in 82.76% of patients. The median extent of resection was 100% (range, 90.6-100%). Eighty-nine samples were harvested, including 70 fluorescence-positive and 19 fluorescence-negative samples. The sensitivity and specificity of IRDye800-BBN were 94.44% (95% CI, 85.65-98.21%) and 88.24% (95% CI, 62.25-97.94%), respectively. Twenty-five patients were followed up (median, 13.5 [3.1-36.0] months), and 14 had died. The mean preoperative and immediate and 6-month postoperative Karnofsky performance scores were 77.9 +/- 11.8, 71.3 +/- 19.2, and 82.6 +/- 14.7, respectively. The median overall and progression-free survival were 23.1 and 14.1 months, respectively. In conclusion, GBM-specific fluorescent IRDye800-BBN can help neurosurgeons identify the tumor boundary with sensitivity and specificity, and may improve survival outcomes.
关键词	fluorescent IRDye800-BBN glioma intraoperative neurosurgery prognosis
DOI	10.1002/btm2.10182
关键词[WOS]	HIGH-GRADE GLIOMAS ; 5-AMINOLEVULINIC ACID ; MALIGNANT GLIOMAS ; GUIDED SURGERY ; PEPTIDE RECEPTOR ; SAFE-RESECTION ; FLUORESCENCE
收录类别	SCI
语种	英语
资助项目	Beijing Nova program[Z201100006820017] ; Beijing Nova program[Z19111000110000] ; National Key R&D Program of China[2017YFA0205200] ; National Key R&D Program of China[2017YFC1309100] ; National Key R&D Program of China[2016YFC0103803] ; National Key R&D Program of China[2019YFC0120800] ; National Key R&D Program of China[2018YFC0910602] ; National Key R&D Program of China[2017YFA0700401] ; National Natural Science Foundation of China[81527805] ; National Natural Science Foundation of China[81971668] ; National Natural Science Foundation of China[61901472] ; Key Research Projects in Frontier Science of Chinese Academy of Sciences (CAS)[QYZDJ-SSW-JSC005] ; Key Research Projects in Frontier Science of Chinese Academy of Sciences (CAS)[KFJ-STS-ZDTP-059] ; Capital characteristic Clinical Application Project[Z181100001718196] ; China Postdoctoral Science Foundation[2019M660409] ; Clinical Scientist Supporting grant of Beijing Tiantan Hospital[YSP201902] ; National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health
项目资助者	Beijing Nova program ; National Key R&D Program of China ; National Natural Science Foundation of China ; Key Research Projects in Frontier Science of Chinese Academy of Sciences (CAS) ; Capital characteristic Clinical Application Project ; China Postdoctoral Science Foundation ; Clinical Scientist Supporting grant of Beijing Tiantan Hospital ; National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health
WOS研究方向	Biotechnology & Applied Microbiology ; Engineering ; Pharmacology & Pharmacy
WOS类目	Biotechnology & Applied Microbiology ; Engineering, Biomedical ; Pharmacology & Pharmacy
WOS记录号	WOS:000564200800001
出版者	WILEY
七大方向——子方向分类	医学影像处理与分析
引用统计	被引频次：14[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.ia.ac.cn/handle/173211/40540
专题	中国科学院分子影像重点实验室
通讯作者	Ji, Nan; Zhu, Zhaohui; Tian, Jie; Chen, Xiaoyuan
作者单位	1.Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing, Peoples R China 2.Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, 95 Zhongguancun East Rd, Beijing 100190, Peoples R China 3.Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, 119 South Fourth Ring West Rd, Beijing, Peoples R China 4.China Natl Clin Res Ctr Neurol Dis NCRC ND, Beijing, Peoples R China 5.Chinese Acad Med Sci & Peking Union Med Coll, Dept Nucl Med, Peking Union Med Coll Hosp, 53 Dongdan North St, Beijing, Peoples R China 6.Natl Inst Biomed Imaging & Bioengn NIBIB, Lab Mol Imaging & Nanomed LOMIN, NIH, Bldg 35A,Room GD937,35 Convent Dr, Bethesda, MD 20892 USA 7.Capital Med Univ, Sch Basic Med Sci, Dept Cell Biol, Beijing, Peoples R China 8.Capital Med Univ, Beijing Neurosurg Inst, Dept Neuropathol, Beijing, Peoples R China
第一作者单位	中国科学院自动化研究所
通讯作者单位	中国科学院自动化研究所
推荐引用方式 GB/T 7714	He, Kunshan,Chi, Chongwei,Li, Deling,et al. Resection and survival data from a clinical trial of glioblastoma multiforme-specificIRDye800-BBNfluorescence-guided surgery[J]. BIOENGINEERING & TRANSLATIONAL MEDICINE,2020:9.
APA	He, Kunshan.,Chi, Chongwei.,Li, Deling.,Zhang, Jingjing.,Niu, Gang.,...&Chen, Xiaoyuan.(2020).Resection and survival data from a clinical trial of glioblastoma multiforme-specificIRDye800-BBNfluorescence-guided surgery.BIOENGINEERING & TRANSLATIONAL MEDICINE,9.
MLA	He, Kunshan,et al."Resection and survival data from a clinical trial of glioblastoma multiforme-specificIRDye800-BBNfluorescence-guided surgery".BIOENGINEERING & TRANSLATIONAL MEDICINE (2020):9.